Plasmablastic multiple myeloma is associated with increased vascular endothelial growth factor immunoexpression

Area of Science:

• Hematology
• Oncology
• Cancer Biology

Background:

• The negative prognostic implications of plasmablastic myeloma (MM) are not fully elucidated.
• Investigating the association between aggressive MM subtypes and the bone marrow microenvironment is crucial.

Purpose of the Study:

• To determine if histologically aggressive multiple myeloma (MM) correlates with a more angiogenic bone marrow environment.
• To explore the role of vascular endothelial growth factor (VEGF) in plasmablastic MM.

Main Methods:

• Bone marrow samples from 50 newly diagnosed multiple myeloma patients were analyzed.
• Vascular endothelial growth factor (VEGF) staining intensity in plasma cells was evaluated.
• Microvessel density was assessed in relation to plasmablastic MM features.

Main Results:

• Plasmablastic MM was identified in 12% of patients.
• Plasmablastic MM significantly correlated with moderate/strong VEGF staining in plasma cells (P = 0.036).
• No association was found between plasmablastic MM and increased microvessel density.

Conclusions:

• Increased VEGF expression on plasmablasts suggests a potential mechanism for the adverse prognosis in plasmablastic MM.
• Patients with plasmablastic MM may benefit from anti-angiogenic therapies targeting VEGF.